| DC Field | Value | Language |
|---|
| dc.contributor.author | Baltag, Natalia | |
| dc.date.accessioned | 2019-06-22T12:20:00Z | - |
| dc.date.available | 2019-06-22T12:20:00Z | - |
| dc.date.issued | 2008 | |
| dc.identifier.citation | BALTAG, Natalia. Evoluţia maladiei tiroidiene Graves-Basedow şi importanţa anticorpilor anti-tiroidieni. In: Anale Științifice ale USMF “Nicolae Testemiţanu”. Ed. a 9-a. Chișinău: CEP Medicina, 2008, vol. 3: Probleme actuale în medicina internă, pp. 184-187. | en_US |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/1738 | - |
| dc.description | Catedra Boli interne nr1 FR USMF „N. Testemiţeanu”, SCM „Sfînta Treime” | en_US |
| dc.description.abstract | In Graves’ disease the dosage of TSH antireceptor antibodies can be a helpful element in treatment management. When TSH antireceptor antibodies’ level is increased, it is not recommended to stop the treatment with anti-thyroidians of synthesis, because of the high risk of relapse. Persistence of a high level of anti-TPO antibodies may possibly subsequently result into hypothyroidism.
În cadrul bolii Graves-Basedow, dozarea a anticorpilor anti-receptori TSH poate constitui un element ajutător pentru dirijarea tratamentului: cînd titrul e ridicat, nu e cazul de a sista tratamentul fiind sporit riscul recidivelor. Persistenţa titrului înalt de anticorpi anti-TPO face posibilă instalarea unei ulterioare hipotiroidii. | en_US |
| dc.language.iso | ro | en_US |
| dc.publisher | CEP "Medicina" | en_US |
| dc.title | Evoluţia maladiei tiroidiene Graves-Basedow şi importanţa anticorpilor anti-tiroidieni | en_US |
| dc.title.alternative | Graves-Basedow Disease Evolution and the Importance of Anti-Thyroid Antibodies | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Endocrinologie
|
